Antisense oligonucleotide mediated exon skipping therapy development for Duchenne muscular dystrophy takes more than an oligonucleotide

‘Antisense oligonucleotide mediated exon skipping therapy development for Duchenne muscular dystrophy takes more than an oligonucleotide’​ by Annemieke Aartsma-Rus

29 March 2022, 3-4pm CEST

The speaker is Professor of Translational Genetics at the Department of Human Genetics at the Leiden University Medical Center, the Netherlands. She is also Co-founder and Co-leader of the Dutch Center for RNA Therapeutics (DCRT).